Data from the Taiwan Liver Disease Prevention and Treatment Academic Foundation reveals that among 4,663 participants in an abdominal ultrasound, 2,505 were diagnosed with fatty liver disease, indicating that the prevalence is significantly higher than the global rate. Metabolic-associated fatty liver disease (MAFLD) arises from insulin resistance, leading to elevated blood sugar and fat buildup in liver cells. This accumulation generates free radicals that damage cells, trigger inflammation, and result in fibrosis, worsening liver injury. Often asymptomatic, fatty liver can progress to irreversible complications like cirrhosis and liver failure. Currently, there are no specific treatments; management focuses on weight loss and dietary control, while pharmacological options are limited to patients with concurrent diabetes or hyperlipidemia, without directly addressing fatty liver symptoms.
SDM101’s primary ingredient is Semaglutide, a GLP-1 receptor agonist. Phase II trials by Novo Nordisk demonstrate that Semaglutide injections significantly enhance outcomes for metabolic-associated fatty liver disease. The EndoEase™ platform optimizes Semaglutide for sublingual delivery. This innovation extends painless healthcare to diseases related to metabolic syndrome. Following the success of Phase I safety trials, we will commence Phase II trials for metabolic-associated fatty liver disease, providing a new, pain-free treatment option for patients.
